ClinicalTrials.gg
CompletedNCT03941990LENOXUpdated Nov 17, 2026

Lumbar Puncture in Emergency Under Nitrous OXide

A Phase 4 interventional study of Fixed 50:50 mixture of nitrous oxide and oxygen and Placebo in Pain and Anxiety, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Clermont-Ferrand · Phase 4, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now CompletedResults publication added+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Pain by University Hospital, Clermont-Ferrand — 8 open to participants now, 8 under way, 1 of them phase 3. Pain · University Hospital, Clermont-Ferrand.

Enrollment
16th of 31
88 · median 88
Started
2019
the only one that year
Phase 4
6 of 45
none open now
Registered
27th of 45
by date

Among the 45 studies in Pain by University Hospital, Clermont-Ferrand, this one is the 16th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2019, is one of 6 in phase 4, and was the 27th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

8 of the 45 studies in Pain by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Pain by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

Lumbar puncture (LP) is a frequent exam that can cause pain and anxiety. In a scheduled setting, it has been shown that nitrous oxide use during the procedure was able to reduce both pain and anxiety. The goal of this trial is to confirm these results in a more heterogeneous group of patients having a LP, in an emergency setting.

Read the detailed description

Nitrous oxide (N2O) has analgesic and anxiolytic properties that are known for more than a century. Nonetheless, it's use during lumbar puncture in adults has only been investigated in a scheduled setting.Thus, this study is designed to evaluate the analgesic effect of N2O on the pain induced during lumbar puncture.

Patients with urgent lumbar puncture realized for diagnosis purposes will be randomized in 2 groups. One group will inhale N2O for the 5 minutes before the puncture and during the rest of the procedure. The second group will inhale compressed air during the same period. Neither the investigator realizing the lumbar puncture, nor the patient will know which type of gaz they are inhaling (double-blinding).

The maximal pain level that occurred during the procedure will be evaluated on a Numerical Rating Scale (NRS). NRS will also be used to evaluate the maximal anxiety induced by the procedure.

03

Conditions studied

  • Pain
  • Anxiety

Keywords

  • Spinal puncture
  • Nitrous oxide
  • Pain
  • Anxiety
  • Emergency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients coming in emergency service who need a lumbar puncture in emergency for a diagnostic purpose
  • at least 18
  • affiliated to the French state healthcare insurance system
  • able to give consent to participation

Exclusion criteria

Exclusion Criteria:

  • Previous use of nitrous oxide (medical or recreational)
  • to nitrous oxide use
  • Face mask phobia
  • Stage II obesity ( > 35)
  • Hemodynamic instability and/or any case when coagulation results cannot be waited
  • Cognitive condition defined by a previous \< 24/30
  • Confusion or any consciousness disorder that might interfere with judgment or consent
  • Patient unable to communicate verbally
  • Patient placed under a legal protection measure (tutorship, curatorship or a mandate)
  • Any medical condition that might contra-indicate medical research, in physician's opinion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Nitrous oxyde

    will inhale experimental treatment throughout the entire procedure (50% N2O - 50% 02)

    Drug: Fixed 50:50 mixture of nitrous oxide and oxygen

  • Placebo comparator
    Placebo

    will inhale medical air throughout the entire procedure (22% O2 + N2 Q.S.)

    Other: Placebo

Interventions

  • DrugFixed 50:50 mixture of nitrous oxide and oxygen

    Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.

  • OtherPlacebo

    inhale medical air (22% O2 - 78% N2)

06

What researchers measure

Primary outcomes

  1. Maximal pain perceived during the lumbar puncture evaluated using a simple numeric 0-10 pain scale

    Maximal level of pain during lumbar puncture. The patient will be asked to circle the digit that best describes the maximal level of pain felt during the procedure. If the patient is too painful and/or is incapacitated, the collection notebook will be fulfilled by the care provider after asking the following question: "On a scale of 0 to 10, 0 being the absence of pain and 10 the maximal pain you can imagine, what is the digit best describing the maximal pain you felt during the procedure?"

    Time frame: 2-3 minutes after the end of gas inhalation

Secondary outcomes

  1. Maximal anxiety perceived during lumbar puncture evaluated using a simple numeric 0-10 scale

    Proportion of patients with significant anxiety

    Time frame: 2-3 minutes after the end of gas inhalation

  2. Side effects

    Every side effect reported by the patients attributable to gas inhalation during the procedure up to emergency service discharge. Presence, intensity and reversibility will be recorded

    Time frame: From the beginning of gas inhalation to a minimum of 2 hours later

  3. Spinal puncture duration

    Comparison of LP duration between both groups measured in minutes (from the beginning of gas inhalation to needle removal).

    Time frame: 2-3 minutes after the end of lumbar puncture

  4. Number of attempts before successful LP

    Comparison of number of attempts needed to get spinal fluid, defined as number of needle removals for a single exam.

    Time frame: 2-3 minutes after the end of lumbar puncture

  5. Patient Satisfaction

    overall satisfaction based on a 0-10 score and proportion of patients that would accept another lumbar puncture in the same conditions

    Time frame: 2-3 minutes after the end of gas inhalation

  6. Blinding quality

    Assessment of blinding in clinical trials (according to Bang et al. 2004)

    Time frame: 2-3 minutes after the end of gas inhalation

  7. Induced cost

    supplementary cost induced by the use of nitrous oxide inhalation for a total of 88 patients throughout the study (gas and consumables such as masks and pipes)

    Time frame: through study completion, an average 4 months

07

Study locations

1 site
  • CHU de Clermont-Ferrand
    Clermont-Ferrand, Auvergne-Rhône-Alpes 63000, France
08

References and documents

Publications

  • Herres J, Chudnofsky CR, Manur R, Damiron K, Deitch K. The use of inhaled nitrous oxide for analgesia in adult ED patients: a pilot study. Am J Emerg Med. 2016 Feb;34(2):269-73. doi: 10.1016/j.ajem.2015.10.038. Epub 2015 Oct 24. PubMed 26585197 ↗
  • Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials. 2004 Apr;25(2):143-56. doi: 10.1016/j.cct.2003.10.016. PubMed 15020033 ↗
  • Koscielniak-Nielsen Z, Hesselbjerg L, Brushoj J, Jensen MB, Pedersen HS. EMLA patch for spinal puncture. A comparison of EMLA patch with lignocaine infiltration and placebo patch. Anaesthesia. 1998 Dec;53(12):1218-22. doi: 10.1046/j.1365-2044.1998.00608.x. PubMed 10193230 ↗
  • Lavi R, Yarnitsky D, Rowe JM, Weissman A, Segal D, Avivi I. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4. doi: 10.1212/01.wnl.0000240054.40274.8a. PubMed 17060584 ↗
  • Lukas A, Niederecker T, Gunther I, Mayer B, Nikolaus T. Self- and proxy report for the assessment of pain in patients with and without cognitive impairment: experiences gained in a geriatric hospital. Z Gerontol Geriatr. 2013 Apr;46(3):214-21. doi: 10.1007/s00391-013-0475-y. PubMed 23474866 ↗
  • Moisset X, Ruet A, Brochet B, Planche V, Jaffeux P, Gilleron V, Ong N, Clavelou P. Who Performs Lumbar Puncture, How Many Do They Perform, How and Why? A Retrospective Study of 6,594 Cases. Eur Neurol. 2016;76(1-2):8-11. doi: 10.1159/000447452. Epub 2016 Jun 24. PubMed 27336667 ↗
  • Moisset X, Sia MA, Pereira B, Taithe F, Dumont E, Bernard L, Clavelou P. Fixed 50:50 mixture of nitrous oxide and oxygen to reduce lumbar-puncture-induced pain: a randomized controlled trial. Eur J Neurol. 2017 Jan;24(1):46-52. doi: 10.1111/ene.13127. Epub 2016 Sep 25. PubMed 27666149 ↗
  • Nicot M, Miraillet L, Pereira B, Bouillon-Minois JB, Raconnat J, Moustafa F, Schmidt J, Sickout-Arondo S, Bernard L, Clavelou P, Moisset X. The Use of a Fixed 50:50 Mixture of Nitrous Oxide and Oxygen to Reduce Lumbar Puncture-Induced Pain in the Emergency Department: A Randomized Controlled Trial. J Clin Med. 2022 Mar 9;11(6):1489. doi: 10.3390/jcm11061489. PubMed 35329815 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Oct 2020, 10 months.

Of 280 non-industry phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 10 months is below that.

Counting every sponsor, half of 295 studies reached it within 18 months; a quarter within 8 and three quarters within 33.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Apr 2020 → Oct 2020 and completion Sep 2020 → Oct 2020.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2019
First posted
May 8, 2019
StartActual
Nov 27, 2019
Primary completionActual
Oct 5, 2020was Apr 2020
CompletionActual
Oct 5, 2020was Sep 2020
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Sites
1 site added, 1 site removed
Show site
  • CHU de Clermont-Ferrand · Clermont-Ferrand, France
Show 1 removed
  • CHU de Clermont-Ferrand · Clermont-Ferrand, France
Nov 17, 2026
Primary completion
Apr 2020→Oct 5, 2020 (actual)
Nov 17, 2026
Study completion
Sep 2020→Oct 5, 2020 (actual)
Nov 17, 2026
Publications
Results publication added: Nicot M, Miraillet L, Pereira B, Bouillon-Minois JB, Raconnat J, Moustafa F, Schmidt J, Sickout-Arondo S, Bernard L, Clavelou P, Moisset X. The Use of a Fixed… PubMed 35329815 ↗
Nov 17, 2026
Sponsor
Collaborators added: Institut National de la Santé Et de la Recherche Médicale, France; collaborators removed: Inserm U1107, NeuroDol
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Publications Results publication added: Nicot M, Miraillet L, Pereira B, Bouillon-Minois JB, Raconnat J, Moustafa F, Schmidt J, Sickout-Arondo S, Bernard L, Clavelou P, Moisset X. The Use of a Fixed… PubMed 35329815 ↗
    1 site added, 1 site removed
    Show site
    • CHU de Clermont-Ferrand · Clermont-Ferrand, France
    Show 1 removed
    • CHU de Clermont-Ferrand · Clermont-Ferrand, France
    Primary completion Apr 2020→Oct 5, 2020 (now actual)
    Study completion Sep 2020→Oct 5, 2020 (now actual)
    Sponsor Collaborators added: Institut National de la Santé Et de la Recherche Médicale, France; collaborators removed: Inserm U1107, NeuroDol
    + 2 other changes: identifiers and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03941990
Responsible party
Sponsor
First posted
May 8, 2019
Start date
Nov 27, 2019
Primary completion
Oct 5, 2020
Completion
Oct 5, 2020
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion